Our Mission: Improving and Extending the Lives of Patients with Cancer
 
 
 

Management

Arthur C. Louie, M.D.
Chief Medical Officer

Dr. Louie is a board certified oncologist with more than 25 years of experience in pharmaceutical research and development. He was a vice president of medical affairs at Human Genome Sciences Inc. and a vice president of clinical research at Xoma Corporation. He also held leadership roles in clinical development at Pro-Neuron, Inc.,
Pro-Virus Inc., and Chiron Therapeutics. Dr. Louie was a director of cancer research at Bristol-Myers and consulted for Johnson & Johnson and Genta Incorporated. He was responsible for the successful effort to secure FDA approval for Proleukin IL-2, which is used for the treatment of metastatic kidney cancer and for metastatic melanoma. Dr. Louie received a B.A. in Biology with honors from Haverford College, and an M.D. from New York University School of Medicine. He completed oncology fellowships at the National Cancer Institute and at Stanford University.

< return

 

 

 


Celator is pioneering a new approach to combination chemotherapy based on synergistic drug ratios.

 

 

 

 
© 2009 Celator Pharmaceuticals, Inc. All rights reserved. Celator®, Celator Pharmaceuticals®, the Celator logo and CombiPlex® are registered trademarks of Celator Pharmaceuticals, Inc. Contact webmaster.